KYNB
KYNTRA BIO, INC.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$5.28
+8.87%Oct 6, 2026, 20:14 UTC
KYNTRA BIO, INC. reported receiving a NASDAQ, INC. notice concerning noncompliance with Rule 5450(b) and requested a hearing.
Oct 1, 2026, 11:31 UTC
Kyntra Bio, Inc. appointed Andrew E. Singer as a Class III director effective October 1, 2026.
Oct 1, 2026, 11:31 UTC
Maykin Ho resigned as a director of Kyntra Bio, Inc. effective September 30, 2026.
Oct 1, 2026, 11:31 UTC
Kyntra Bio, Inc. entered into a new employment agreement with CEO Thane Wettig effective September 30, 2026, on substantially the same severance and change-in-control terms as his prior agreement.
Aug 31, 2026, 20:05 UTC
Kyntra Bio signed an amendment and restatement of its royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations in exchange for an accelerated upfront payment.
Source:Aug 13, 2026, 20:02 UTC
Kyntra Bio reported its financial results for the second quarter of 2026.